<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01117350</url>
  </required_header>
  <id_info>
    <org_study_id>LANTU_C_03680</org_study_id>
    <secondary_id>2010-018437-21</secondary_id>
    <secondary_id>U1111-1116-9684</secondary_id>
    <nct_id>NCT01117350</nct_id>
  </id_info>
  <brief_title>Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure</brief_title>
  <acronym>EAGLE</acronym>
  <official_title>A 24-week, Multicenter, International, Randomized (1:1), Parallel-group, Open-label, Comparative Study of Insulin Glargine Versus Liraglutide in Insulin-naïve Patients With Type 2 Diabetes Treated With Oral Agents and Not Adequately Controlled, Followed by a 24-week Extension Period With Insulin Glargine for Patients Not Adequately Controlled With Liraglutide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary objective:

      To demonstrate the superiority of insulin glargine over liraglutide in terms of percentage of
      patients reaching a Glycosylated Haemoglobin (HbA1c) &lt; 7% at the end of the comparative
      period (24 weeks) in Type 2 diabetic patients failing lifestyle management and oral agents

      Secondary objectives of the comparative period (24 weeks):

      &gt;To assess the effect of insulin glargine in comparison with liraglutide on:

        -  HbA1c level

        -  Percentage of patients whose HbA1c has decreased but remains &gt;= 7% at the end of the
           comparative period

        -  Percentage of patients whose HbA1c has increased at the end of the comparative period

        -  Fasting Plasma Glucose (FPG)

        -  7-point Plasma Glucose (PG) profiles

        -  Hypoglycemia occurrence

        -  Body weight

        -  Adverse events

      Objectives of the extension period (24 weeks):

      &gt;To assess the effect of insulin glargine in patients not adequately controlled with
      liraglutide on:

        -  HbA1c level

        -  FPG

        -  7-point PG profiles

        -  Hypoglycemia occurrence

        -  Body weight

        -  Adverse events
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Maximum estimated study duration per patient: either 27 weeks (patients randomized to insulin
      glargine arm) or 51 weeks (patients randomized to liraglutide arm) broken down as follow:

        -  A 2-week of screening period,

        -  A 24-week comparative period,

        -  A 24-week extension period (only for patients treated with liraglutide, not adequately
           controlled at the end of the comparative period),

        -  A 1-week follow-up period
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients Whose Glycosylated Haemoglobin (HbA1c) &lt;7% at the End of the Comparative Period</measure>
    <time_frame>week 12, week 24</time_frame>
    <description>The value at the end of the comparative period was defined as the last available HbA1c value measured during the comparative period plus 14 days after the last dose of Investigational Product (i.e. last-observation-carried-forward [LOCF] value).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Whose Glycosylated Haemoglobin (HbA1c) Has Decreased But Remains ≥7% at the End of the Comparative Period</measure>
    <time_frame>baseline (week -2), week 12, week 24</time_frame>
    <description>Percentage of patients with:
* HbA1c value at end of the comparative period (LOCF) lower than HbA1c baseline value
AND
* HbA1c value at end of the comparative period (LOCF) ≥7%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Whose Glycosylated Haemoglobin (HbA1c) Has Increased at the End of the Comparative Period</measure>
    <time_frame>baseline (week -2), week 12, week 24</time_frame>
    <description>Percentage of patients with HbA1c value at end of the comparative period (LOCF) higher than HbA1c baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycosylated Haemoglobin (HbA1c): Change From Baseline to the End of Comparative Period</measure>
    <time_frame>baseline (week -2), week 12, week 24</time_frame>
    <description>Change in HbA1C from baseline to the last observation carried forward (LOCF) measured during the comparative period = LOCF value - baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycosylated Haemoglobin (HbA1c): Change From Beginning to the End of the Extension Period</measure>
    <time_frame>week 24, week 36, week 48</time_frame>
    <description>Change in HbA1C from beginning of the extension period (week 24) to the last observation carried forward (LOCF) measured during the extension period = LOCF value - week 24 value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Whose Glycosylated Haemoglobin (HbA1c) &lt;7% at the End of the Extension Period</measure>
    <time_frame>week 36, week 48</time_frame>
    <description>Value at the end of the extension period defined as last available HbA1c value measured during the extension period (i.e. last observation carried forward (LOCF) value)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-Monitored Fasting Plasma Glucose (SMFPG) Measurements: Change From Baseline to the End of the Comparative Period</measure>
    <time_frame>baseline (week 0), week 6, week 12, week 18, week 24</time_frame>
    <description>SMFPG = mean value of Self-Monitored Fasting Plasma Glucose measurements over 3 consecutive days in the week before each visit
Value at the end of the comparative period defined as last available value during the comparative period (i.e. last-observation-carried-forward [LOCF] value)
Change = LOCF value - baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-Monitored Fasting Plasma Glucose (SMFPG) Measurements: Change From Beginning to the End of the Extension Period</measure>
    <time_frame>week 24, week 30, week 36, week 48</time_frame>
    <description>SMFPG = mean value of Self-Monitored Fasting Plasma Glucose measurements over 3 consecutive days in the week before each visit
Value at the end of the extension period defined as last available value during the extension period (i.e. last-observation-carried-forward [LOCF] value)
Change = LOCF value - week 24 value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-Monitored 7-point Plasma Glucose (PG) Profile: Change From Baseline to the End of the Comparative Period</measure>
    <time_frame>baseline (week 0), week 12, week 24</time_frame>
    <description>Self-monitored 7-point plasma glucose profiles (before and 2 hours after the start of breakfast, lunch and dinner, and at bedtime) recorded on 3 consecutive days in the week before each visit
Value at the end of the comparative period defined as last available value during the comparative period (i.e. last-observation-carried-forward [LOCF] value)
Change = LOCF value - baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-Monitored 7-point Plasma Glucose (PG) Profile: Change From Beginning to the End of the Extension Period</measure>
    <time_frame>week 24, week 36, week 48</time_frame>
    <description>Self-monitored 7-point plasma glucose profiles (before and 2 hours after the start of breakfast, lunch and dinner, and at bedtime) recorded on 3 consecutive days in the week before each visit
Value at the end of the extension period defined as last available value during the extension period (i.e. last-observation-carried-forward [LOCF] value)
Change = LOCF value - week 24 value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Weight: Change From Baseline to the End of the Comparative Period</measure>
    <time_frame>baseline (week 0), week 2, week 6, week 12, week 18, week 24</time_frame>
    <description>Change = Last weight value measured during the comparative period (LOCF value) - weight value at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Weight: Change From Beginning to End of the Extension Period</measure>
    <time_frame>week 24, week 30, week 36, week 48</time_frame>
    <description>Change = Last weight value measured during the extension period (LOCF value) - weight value at beginning of the Extension Period (Week 24)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily Dose of Insulin Glargine</measure>
    <time_frame>week 1, week 2, week 6, week 12, week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily Dose of Liraglutide</measure>
    <time_frame>week 1, week 2, week 6, week 12, week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily Dose of Insulin Glargine Administered During the Extension Period</measure>
    <time_frame>week 30, week 36, week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemia Occurence: Number of Patients With at Least One Episode of Symptomatic / Severe Symptomatic Hypoglycemia During the Comparative Period</measure>
    <time_frame>all across the comparative period (from week 0 to week 24)</time_frame>
    <description>Symptomatic hypoglycemia was defined as an event with clinical symptoms that were considered to result from hypoglycemia.
Severe symptomatic hypoglycemia was defined as an event with clinical symptoms that were considered to result from hypoglycemia, requiring the assistance of another person for active administration of carbohydrate, glucagon or other countermeasure because the patient could not treat him/herself due to acute neurological impairment directly resulting from the hypoglycemia (assistance by another person when the patient could have treated him/herself was not considered as requiring assistance)and one of the following criteria:
The event was associated with a measured PG level &lt; 36 mg/dL (2 mmol/L),
Or, in absence of PG value, the event was associated with neurological recovery attributable to the restoration of PG to normal, after oral carbohydrate, intravenous glucose or glucagon administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemia Occurence: Number of Patients With at Least One Episode of Symptomatic / Severe Symptomatic Hypoglycemia During the Extension Period</measure>
    <time_frame>all across the extension period (from week 24 to week 48)</time_frame>
    <description>Symptomatic hypoglycemia was defined as an event with clinical symptoms that were considered to result from hypoglycemia.
Severe symptomatic hypoglycemia was defined as an event with clinical symptoms that were considered to result from hypoglycemia, requiring the assistance of another person for active administration of carbohydrate, glucagon or other countermeasure because the patient could not treat him/herself due to acute neurological impairment directly resulting from the hypoglycemia (assistance by another person when the patient could have treated him/herself was not considered as requiring assistance)and one of the following criteria:
The event was associated with a measured PG level &lt; 36 mg/dL (2 mmol/L),
Or, in absence of PG value, the event was associated with neurological recovery attributable to the restoration of PG to normal, after oral carbohydrate, intravenous glucose or glucagon administration.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">978</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Insulin Glargine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin glargine administered once a day, in the morning or in the evening, at the most convenient time. The time of injection, once chosen was to remain unchanged during the whole duration of the study.
The starting dose was 0.2 Unit per kilogram of body weight or 10 Units. Patients were empowered to adjust their insulin doses, under strict investigator's supervision. Insulin titration (by 2 or 4 Units) was done every 3 days according to the median value of Fasting Plasma Glucose (FPG) of the last 3 days. The goal was to achieve 70 &lt; FPG ≤ 100 mg/dL (3.9 &lt; FPG ≤ 5.5 mmol/L). Minor deviations from the titration scheme could be allowed, based on Investigator's judgment and patient's situation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liraglutide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Liraglutide administered once a day, in the morning or in the evening, at the most convenient time. The time of injection , once chosen was to remain unchanged during the whole duration of the study.
The dose was 0.6 mg/day during the first week, 1.2 mg/day during the second week and 1.8 mg/day until week 24. The dose might be decreased to 1.2 mg for safety reasons (e.g. gastro-intestinal tolerability), based on Investigator's judgment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin glargine</intervention_name>
    <description>100 Units/mL solution for injection in a pre-filled SoloStar pen</description>
    <arm_group_label>Insulin Glargine</arm_group_label>
    <other_name>Lantus®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <description>6 mg/mL solution for injection in a 3-mL pre-filled pen (18mg)</description>
    <arm_group_label>Liraglutide</arm_group_label>
    <other_name>Victoza®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin was a background treatment, mandatory for each patient randomized in the study (at the minimum dose of 1g/day). It was not supplied by the sponsor.</description>
    <arm_group_label>Insulin Glargine</arm_group_label>
    <arm_group_label>Liraglutide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria (comparative period):

          -  Patients With Type 2 Diabetes diagnosed for at least 1 year,

          -  Treated with lifestyle interventions and metformin at the maximum tolerated dosage
             (with a minimum daily dosage of 1g), either alone or in combination with an oral
             insulin secretagogue (sulfonylurea, glinide or DiPeptidyl Peptidase IV inhibitor), for
             more than 3 months,

          -  7.5% &lt; HbA1c &lt;= 12%,

          -  Body Mass Index (BMI) between 25 and 40 kg/m2 inclusively,

          -  Ability and willingness to perform PG (Plasma Glucose) self monitoring using the
             sponsor-provided glucose meter and to complete the patient diary,

          -  Willingness and ability to comply with the study protocol,

          -  Signed informed consent obtained prior to any study procedure.

        Inclusion criteria (extension period):

          -  Patients treated with liraglutide (at the maximal tolerated dosage), having a mean FPG
             ≥ 250 mg/dL at visit 10 (Week 12) or visit 11 (Week 18), or a HbA1c≥ 7% at visit 12
             (Week 24)

          -  Dosage of metformin compliant with the inclusion criteria of visit 1 (i.e. maximum
             tolerated dosage, with a minimum daily dosage of 1g), and maintained stable during the
             comparative period.

        Exclusion criteria:

          -  Previous treatment with Glucagon Like Peptide-1 analogues or insulin in the past year
             (except in case of temporary treatment for gestational diabetes, surgery,
             hospitalization...),

          -  Treatment with thiazolidinediones or α-Glucosidases inhibitors within 3 months prior
             to study entry,

          -  Diabetes other than Type 2 diabetes (e.g. secondary to pancreatic disorders, drug or
             chemical agents intake),

          -  Pregnant women (women of childbearing potential must have a negative pregnancy test at
             study entry and a medically approved contraceptive method),

          -  Lactating women,

          -  Hospitalized patients (except hospitalization for routine diabetes check-up),

          -  Active proliferative retinopathy, as defined by a photocoagulation or vitrectomy
             occurrence in the 6 months prior to study entry, or any other unstable (rapidly
             progressing) retinopathy that may require photocoagulation or surgical treatment
             during the study, documented by a retina examination within 2 years prior to study
             entry,

          -  Impaired renal function (creatinine clearance &lt; 60 mL/mn),

          -  Impaired hepatic function (Alanine Aminotransferase, Aspartate Aminotransferase 2.5
             times the upper limit of normal range),

          -  Personal or family history of medullary thyroid carcinoma,

          -  Multiple endocrine neoplasia syndrome type 2,

          -  Severe gastro-intestinal disease (including inflammatory bowel disease or diabetic
             gastroparesis),

          -  Congestive heart failure,

          -  History of acute pancreatitis,

          -  Treatment with corticosteroids with potential systemic action for more than 10 days
             within 3 months prior to study entry,

          -  Alcohol or drug abuse in the past 5 years,

          -  History of sensitivity to the study drugs or to drugs with a similar chemical
             structure.

          -  Night shift worker,

          -  Presence of any condition (medical, psychological, social or geographical), current or
             anticipated that would compromise the patients safety or limit the patient successful
             participation in the study,

          -  Participation in a clinical trial (drug or device) within 3 months prior to study
             entry,

          -  Refusal or inability to give informed consent to participate in the study,

          -  Patient is the Investigator or any sub-Investigator, research assistant, pharmacist,
             study coordinator, other staff or relative thereof directly involved in the conduct of
             the protocol.

        Additional exclusion criteria for the extension period:

          -  Treatment with oral antidiabetic drugs other than metformin and patient's usual
             sulfonylurea if any, or with insulin during the comparative period (except in case of
             an emergency, for a period of time less than 7 days),

          -  Treatment with corticosteroids with potential systemic action within the last 3 months
             of the comparative period.

          -  History of sensitivity to insulin glargine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 840023</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840002</name>
      <address>
        <city>Goodyear</city>
        <state>Arizona</state>
        <zip>85395</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840047</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840017</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840036</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840037</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92357</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840045</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840048</name>
      <address>
        <city>Mission Hills</city>
        <state>California</state>
        <zip>91345</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840033</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840019</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <zip>92262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840039</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840042</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840043</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840028</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840034</name>
      <address>
        <city>Grand Junction</city>
        <state>Colorado</state>
        <zip>81501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840026</name>
      <address>
        <city>Longmont</city>
        <state>Colorado</state>
        <zip>80501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840022</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840029</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840009</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840051</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840050</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46222</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840031</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840004</name>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <zip>42003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840010</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840038</name>
      <address>
        <city>Eagan</city>
        <state>Minnesota</state>
        <zip>55122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840030</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840012</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840044</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840015</name>
      <address>
        <city>Atco</city>
        <state>New Jersey</state>
        <zip>08004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840008</name>
      <address>
        <city>Blackwood</city>
        <state>New Jersey</state>
        <zip>08012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840027</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840011</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10301-3914</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840005</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840052</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840049</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840006</name>
      <address>
        <city>Bryan</city>
        <state>Ohio</state>
        <zip>43506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840035</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840016</name>
      <address>
        <city>Carnegie</city>
        <state>Pennsylvania</state>
        <zip>15106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840020</name>
      <address>
        <city>Uniontown</city>
        <state>Pennsylvania</state>
        <zip>15401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840024</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840001</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840007</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840013</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840014</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840046</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99220-3649</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 040-006</name>
      <address>
        <city>Salzburg</city>
        <zip>5010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 040-007</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 040-003</name>
      <address>
        <city>Stockerau</city>
        <zip>A-2000</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 040-005</name>
      <address>
        <city>Vienna</city>
        <zip>A-1010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 040-002</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 040-001</name>
      <address>
        <city>Vienna</city>
        <zip>A-1130</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 040-004</name>
      <address>
        <city>Vienna</city>
        <zip>A-1220</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076-004</name>
      <address>
        <city>Belém</city>
        <zip>66073-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076-007</name>
      <address>
        <city>Fortaleza</city>
        <zip>60015-052</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076-001</name>
      <address>
        <city>Fortaleza</city>
        <zip>60115-282</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076-006</name>
      <address>
        <city>Fortaleza</city>
        <zip>60430-370</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076-005</name>
      <address>
        <city>Marília</city>
        <zip>17519-101</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076-002</name>
      <address>
        <city>São Paulo</city>
        <zip>01244-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124-003</name>
      <address>
        <city>Mississauga</city>
        <zip>L5M2V8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124-001</name>
      <address>
        <city>Montreal</city>
        <zip>H2W1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124-006</name>
      <address>
        <city>Montreal</city>
        <zip>H3A1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124-004</name>
      <address>
        <city>Toronto</city>
        <zip>M5C 2T2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124-008</name>
      <address>
        <city>Vancouver</city>
        <zip>V5Z1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124-007</name>
      <address>
        <city>Victoria</city>
        <zip>V8R1J8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 203001</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>50005</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 203003</name>
      <address>
        <city>Krnov</city>
        <zip>79401</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 203005</name>
      <address>
        <city>Kromeriz</city>
        <zip>76701</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 203002</name>
      <address>
        <city>Olomouc</city>
        <zip>77900</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 203006</name>
      <address>
        <city>Praha 5</city>
        <zip>15000</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 246003</name>
      <address>
        <city>Harjavalta</city>
        <zip>29200</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 246001</name>
      <address>
        <city>Kuopio</city>
        <zip>70210</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 246002</name>
      <address>
        <city>Oulu</city>
        <zip>90100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 246004</name>
      <address>
        <city>Turku</city>
        <zip>20100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250-007</name>
      <address>
        <city>Annecy</city>
        <zip>74000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250-017</name>
      <address>
        <city>Bois Guillaume Cedex</city>
        <zip>76233</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250-003</name>
      <address>
        <city>Boulogne Billancourt</city>
        <zip>92100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250-011</name>
      <address>
        <city>Brest</city>
        <zip>29000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250-008</name>
      <address>
        <city>Cahors Cedex 9</city>
        <zip>46005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250-012</name>
      <address>
        <city>Corbeil Essonnes</city>
        <zip>91100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250-009</name>
      <address>
        <city>La Rochelle Cedex 1</city>
        <zip>17019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250-004</name>
      <address>
        <city>Le Creusot</city>
        <zip>71200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250-006</name>
      <address>
        <city>Mantes La Jolie</city>
        <zip>78200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250-021</name>
      <address>
        <city>Nanterre</city>
        <zip>92014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250022</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250-020</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250-002</name>
      <address>
        <city>Toulouse</city>
        <zip>31300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250-016</name>
      <address>
        <city>Venissieux</city>
        <zip>69200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 300003</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 300004</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 300001</name>
      <address>
        <city>Haidari, Athens</city>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 372001</name>
      <address>
        <city>Dublin 4</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 376004</name>
      <address>
        <city>Hadera</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 376002</name>
      <address>
        <city>Petah Tiqwa</city>
        <zip>49361</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 376003</name>
      <address>
        <city>Tel-Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 484004</name>
      <address>
        <city>Guadalajara</city>
        <zip>44630</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 484001</name>
      <address>
        <city>Mexico</city>
        <zip>07760</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 484002</name>
      <address>
        <city>Mexico</city>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 484003</name>
      <address>
        <city>Zapopan</city>
        <zip>45200</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 528001</name>
      <address>
        <city>Beek</city>
        <zip>6191JW</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 528006</name>
      <address>
        <city>Enschede</city>
        <zip>7523JJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 528002</name>
      <address>
        <city>Hoogeveen</city>
        <zip>7909AA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 528007</name>
      <address>
        <city>Nijverdal</city>
        <zip>7442LS</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 528003</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 528004</name>
      <address>
        <city>s-Hertogenbosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 528005</name>
      <address>
        <city>Woerden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643-009</name>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643008</name>
      <address>
        <city>Kirov</city>
        <zip>610014K</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643001</name>
      <address>
        <city>Moscow</city>
        <zip>117036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643006</name>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643007</name>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643005</name>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643004</name>
      <address>
        <city>St-Petersburg</city>
        <zip>195257</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643003</name>
      <address>
        <city>St-Ptetersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 703002</name>
      <address>
        <city>Bratislava</city>
        <zip>81102</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 703004</name>
      <address>
        <city>Kosice</city>
        <zip>04013</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 703001</name>
      <address>
        <city>Nitra</city>
        <zip>94911</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 703005</name>
      <address>
        <city>Nove Mesto nad Vahom</city>
        <zip>091501</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 703003</name>
      <address>
        <city>Zilina</city>
        <zip>01001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724007</name>
      <address>
        <city>Bilbao</city>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724006</name>
      <address>
        <city>Cádiz</city>
        <zip>11009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724001</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <zip>35020</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724005</name>
      <address>
        <city>LLeida</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724008</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724003</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724009</name>
      <address>
        <city>Sabadell</city>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 721002</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724004</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724010</name>
      <address>
        <city>Vigo</city>
        <zip>36211</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 752-002</name>
      <address>
        <city>Göteborg</city>
        <zip>41665</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 752-005</name>
      <address>
        <city>Karlskoga</city>
        <zip>69181</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 752-006</name>
      <address>
        <city>Motala</city>
        <zip>59185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 752-001</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 752-03</name>
      <address>
        <city>Ängelholm</city>
        <zip>26281</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 752-007</name>
      <address>
        <city>Örebro</city>
        <zip>70235</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 792-001</name>
      <address>
        <city>Antalya</city>
        <zip>07070</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 792-002</name>
      <address>
        <city>Istanbul</city>
        <zip>34890</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Finland</country>
    <country>France</country>
    <country>Greece</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2010</study_first_submitted>
  <study_first_submitted_qc>May 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2010</study_first_posted>
  <results_first_submitted>October 4, 2013</results_first_submitted>
  <results_first_submitted_qc>December 11, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 29, 2014</results_first_posted>
  <last_update_submitted>March 5, 2014</last_update_submitted>
  <last_update_submitted_qc>March 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first patient was enrolled on July 23, 2010. The 24-week comparative period was completed on October 5, 2012.
The extension period was initiated on March 24, 2011 and completed on March 6, 2013.</recruitment_details>
      <pre_assignment_details>A total of 1456 patients were screened in 136 centers, in 17 countries (Austria, Brazil, Canada, Czech Republic, Finland, France, Greece, Ireland, Israel, Mexico, Netherlands, Russian Federation Slovakia, Spain, Sweden, Turkey, USA). Among them, 478 (32.8%) patients were not randomized (main reason was Glycosylated Haemoglobin A1c out of range).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Insulin Glargine</title>
          <description>Insulin glargine starting dose: 0.2 Unit per kilogram of body weight or 10 Units. Insulin titration (by 2 or 4 Units) every 3 days according to the median value of Fast Plasma Glucose of the last 3 days</description>
        </group>
        <group group_id="P2">
          <title>Liraglutide (Comparative Period)/ Insulin Glargine (Extension)</title>
          <description>Liraglutide dose: 0.6 mg/day during the first week, 1.2 mg/day during the second week and 1.8 mg/day until week 24 (comparative period)
For patients included in the extension period: Insulin Glargine (dosing same as above)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Comparative Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="489">STARTED: randomized</participants>
                <participants group_id="P2" count="489"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>TREATED = Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="484">Safety population: all randomized and treated patients (received at least one dose)</participants>
                <participants group_id="P2" count="481"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>mITT Population</title>
              <participants_list>
                <participants group_id="P1" count="474">modified Intent-To-Treat population: treated patients with at least one efficacy post-baseline value</participants>
                <participants group_id="P2" count="470"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="447"/>
                <participants group_id="P2" count="414"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="75"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not Treated</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Move to another city/country</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extension Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="210">STARTED: patients having completed the comparative period and eligible for the extension period</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>TREATED = Safety Population (Extension)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="160">Safety population (extension): treated with insulin glargine during the extension period</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>mITT Population (Extension)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="154">mITT (extension): treated patients with at least 1 efficacy value both at entry and during extension</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="147"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="63"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not included in extension, not treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inclusion criteria not respected</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Prohibited medication</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Modified-Intent-to-treat (mITT) population: all patients who were randomized, received at least one dose of Interventional Product (IP), and had at least one post-baseline assessment during comparative period of any primary or secondary efficacy variables</population>
      <group_list>
        <group group_id="B1">
          <title>Insulin Glargine</title>
          <description>Insulin glargine starting dose: 0.2 Unit per kilogram of body weight or 10 Units. Insulin titration (by 2 or 4 Units) every 3 days according to the median value of Fast Plasma Glucose of the last 3 days.</description>
        </group>
        <group group_id="B2">
          <title>Liraglutide</title>
          <description>Liraglutide dose: 0.6 mg/day during the first week, 1.2 mg/day during the second week and 1.8 mg/day until week 24.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="474"/>
            <count group_id="B2" value="470"/>
            <count group_id="B3" value="944"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.07" spread="8.78"/>
                    <measurement group_id="B2" value="57.44" spread="8.85"/>
                    <measurement group_id="B3" value="57.25" spread="8.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="224"/>
                    <measurement group_id="B2" value="207"/>
                    <measurement group_id="B3" value="431"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="250"/>
                    <measurement group_id="B2" value="263"/>
                    <measurement group_id="B3" value="513"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI) at week -2</title>
          <units>kg/m²</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.00" spread="4.24"/>
                    <measurement group_id="B2" value="31.75" spread="4.12"/>
                    <measurement group_id="B3" value="31.88" spread="4.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Type 2 diabetes</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.54" lower_limit="5.20" upper_limit="12.38"/>
                    <measurement group_id="B2" value="8.41" lower_limit="4.80" upper_limit="11.69"/>
                    <measurement group_id="B3" value="8.49" lower_limit="4.94" upper_limit="12.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>At least one diabetic late complication</title>
          <description>Diabetic late complications: myocardial infarction, angina pectoris, coronary artery disease, heart failure, stroke, transient ischemic attack, peripheral vascular disease, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="212"/>
                    <measurement group_id="B2" value="223"/>
                    <measurement group_id="B3" value="435"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="262"/>
                    <measurement group_id="B2" value="247"/>
                    <measurement group_id="B3" value="509"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glycosylated Hemoglobin A1c (HbA1c) at week -2</title>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.04" spread="1.10"/>
                    <measurement group_id="B2" value="9.11" spread="1.09"/>
                    <measurement group_id="B3" value="9.07" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients Whose Glycosylated Haemoglobin (HbA1c) &lt;7% at the End of the Comparative Period</title>
        <description>The value at the end of the comparative period was defined as the last available HbA1c value measured during the comparative period plus 14 days after the last dose of Investigational Product (i.e. last-observation-carried-forward [LOCF] value).</description>
        <time_frame>week 12, week 24</time_frame>
        <population>The population analyzed for this outcome measure consisted of the subset of mITT patients who had at least one HbA1c value on treatment during the comparative period.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine</title>
            <description>Insulin glargine starting dose: 0.2 Unit per kilogram of body weight or 10 Units. Insulin titration (by 2 or 4 Units) every 3 days according to the median value of Fast Plasma Glucose of the last 3 days.</description>
          </group>
          <group group_id="O2">
            <title>Liraglutide</title>
            <description>Liraglutide dose: 0.6 mg/day during the first week, 1.2 mg/day during the second week and 1.8 mg/day until week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Whose Glycosylated Haemoglobin (HbA1c) &lt;7% at the End of the Comparative Period</title>
          <description>The value at the end of the comparative period was defined as the last available HbA1c value measured during the comparative period plus 14 days after the last dose of Investigational Product (i.e. last-observation-carried-forward [LOCF] value).</description>
          <population>The population analyzed for this outcome measure consisted of the subset of mITT patients who had at least one HbA1c value on treatment during the comparative period.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="467"/>
                <count group_id="O2" value="458"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.4"/>
                    <measurement group_id="O2" value="45.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority testing
H0: Rate measured with insulin glargine = rate measured with liraglutide
H1: Rate measured with insulin glargine ≠ rate measured with liraglutide
Sample size calculation (465 randomized patients per arm) was based on the assumption of an expected success rate of 46% with insulin glargine and 35% with liraglutide, an alpha risk of 5% (2-sided) and a power of 90%, taking into account an estimated non evaluability rate of 10%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.439</p_value>
            <p_value_desc>If superiority not demonstrated, switching from superiority to non-inferiority considered.
Conclusion of non-inferiority reached if lower limit of 2-sided 95% confidence interval of the difference (insulin glargine – liraglutide) &gt; or = to - 3.5%</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.88</ci_lower_limit>
            <ci_upper_limit>8.93</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Whose Glycosylated Haemoglobin (HbA1c) Has Decreased But Remains ≥7% at the End of the Comparative Period</title>
        <description>Percentage of patients with:
* HbA1c value at end of the comparative period (LOCF) lower than HbA1c baseline value
AND
* HbA1c value at end of the comparative period (LOCF) ≥7%</description>
        <time_frame>baseline (week -2), week 12, week 24</time_frame>
        <population>The population analyzed for this outcome measure consisted of the subset of mITT patients who had at least one HbA1c value on treatment during the comparative period.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine</title>
            <description>Insulin glargine starting dose: 0.2 Unit per kilogram of body weight or 10 Units. Insulin titration (by 2 or 4 Units) every 3 days according to the median value of Fast Plasma Glucose of the last 3 days.</description>
          </group>
          <group group_id="O2">
            <title>Liraglutide</title>
            <description>Liraglutide dose: 0.6 mg/day during the first week, 1.2 mg/day during the second week and 1.8 mg/day until week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Whose Glycosylated Haemoglobin (HbA1c) Has Decreased But Remains ≥7% at the End of the Comparative Period</title>
          <description>Percentage of patients with:
* HbA1c value at end of the comparative period (LOCF) lower than HbA1c baseline value
AND
* HbA1c value at end of the comparative period (LOCF) ≥7%</description>
          <population>The population analyzed for this outcome measure consisted of the subset of mITT patients who had at least one HbA1c value on treatment during the comparative period.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="467"/>
                <count group_id="O2" value="458"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.1"/>
                    <measurement group_id="O2" value="46.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Whose Glycosylated Haemoglobin (HbA1c) Has Increased at the End of the Comparative Period</title>
        <description>Percentage of patients with HbA1c value at end of the comparative period (LOCF) higher than HbA1c baseline value</description>
        <time_frame>baseline (week -2), week 12, week 24</time_frame>
        <population>The population analyzed for this outcome measure consisted of the subset of mITT patients who had at least one HbA1c value on treatment during the comparative period.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine</title>
            <description>Insulin glargine starting dose: 0.2 Unit per kilogram of body weight or 10 Units. Insulin titration (by 2 or 4 Units) every 3 days according to the median value of Fast Plasma Glucose of the last 3 days.</description>
          </group>
          <group group_id="O2">
            <title>Liraglutide</title>
            <description>Liraglutide dose: 0.6 mg/day during the first week, 1.2 mg/day during the second week and 1.8 mg/day until week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Whose Glycosylated Haemoglobin (HbA1c) Has Increased at the End of the Comparative Period</title>
          <description>Percentage of patients with HbA1c value at end of the comparative period (LOCF) higher than HbA1c baseline value</description>
          <population>The population analyzed for this outcome measure consisted of the subset of mITT patients who had at least one HbA1c value on treatment during the comparative period.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="467"/>
                <count group_id="O2" value="458"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1"/>
                    <measurement group_id="O2" value="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glycosylated Haemoglobin (HbA1c): Change From Baseline to the End of Comparative Period</title>
        <description>Change in HbA1C from baseline to the last observation carried forward (LOCF) measured during the comparative period = LOCF value - baseline value</description>
        <time_frame>baseline (week -2), week 12, week 24</time_frame>
        <population>The population analyzed for this outcome measure consisted of the subset of mITT patients who had at least one HbA1c value on treatment during the comparative period.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine</title>
            <description>Insulin glargine starting dose: 0.2 Unit per kilogram of body weight or 10 Units. Insulin titration (by 2 or 4 Units) every 3 days according to the median value of Fast Plasma Glucose of the last 3 days.</description>
          </group>
          <group group_id="O2">
            <title>Liraglutide</title>
            <description>Liraglutide dose: 0.6 mg/day during the first week, 1.2 mg/day during the second week and 1.8 mg/day until week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Glycosylated Haemoglobin (HbA1c): Change From Baseline to the End of Comparative Period</title>
          <description>Change in HbA1C from baseline to the last observation carried forward (LOCF) measured during the comparative period = LOCF value - baseline value</description>
          <population>The population analyzed for this outcome measure consisted of the subset of mITT patients who had at least one HbA1c value on treatment during the comparative period.</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="467"/>
                <count group_id="O2" value="458"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.92" spread="1.22"/>
                    <measurement group_id="O2" value="-1.81" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glycosylated Haemoglobin (HbA1c): Change From Beginning to the End of the Extension Period</title>
        <description>Change in HbA1C from beginning of the extension period (week 24) to the last observation carried forward (LOCF) measured during the extension period = LOCF value - week 24 value</description>
        <time_frame>week 24, week 36, week 48</time_frame>
        <population>The population analyzed for this outcome measure consisted of the subset of mITT population (extension) who had HbA1c value both at beginning of the extension and at least one value on treatment during the extension period.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine (Extension Period)</title>
            <description>Insulin glargine starting dose: 0.2 Unit per kilogram of body weight or 10 Units. Insulin titration (by 2 or 4 Units) every 3 days according to the median value of Fast Plasma Glucose of the last 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Glycosylated Haemoglobin (HbA1c): Change From Beginning to the End of the Extension Period</title>
          <description>Change in HbA1C from beginning of the extension period (week 24) to the last observation carried forward (LOCF) measured during the extension period = LOCF value - week 24 value</description>
          <population>The population analyzed for this outcome measure consisted of the subset of mITT population (extension) who had HbA1c value both at beginning of the extension and at least one value on treatment during the extension period.</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.26" spread="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Whose Glycosylated Haemoglobin (HbA1c) &lt;7% at the End of the Extension Period</title>
        <description>Value at the end of the extension period defined as last available HbA1c value measured during the extension period (i.e. last observation carried forward (LOCF) value)</description>
        <time_frame>week 36, week 48</time_frame>
        <population>The population analyzed for this outcome measure consisted of the mITT patients who had at least one HbA1c value on treatment during the extension period.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine (Extension Period)</title>
            <description>Insulin glargine starting dose: 0.2 Unit per kilogram of body weight or 10 Units. Insulin titration (by 2 or 4 Units) every 3 days according to the median value of Fast Plasma Glucose of the last 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Whose Glycosylated Haemoglobin (HbA1c) &lt;7% at the End of the Extension Period</title>
          <description>Value at the end of the extension period defined as last available HbA1c value measured during the extension period (i.e. last observation carried forward (LOCF) value)</description>
          <population>The population analyzed for this outcome measure consisted of the mITT patients who had at least one HbA1c value on treatment during the extension period.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Self-Monitored Fasting Plasma Glucose (SMFPG) Measurements: Change From Baseline to the End of the Comparative Period</title>
        <description>SMFPG = mean value of Self-Monitored Fasting Plasma Glucose measurements over 3 consecutive days in the week before each visit
Value at the end of the comparative period defined as last available value during the comparative period (i.e. last-observation-carried-forward [LOCF] value)
Change = LOCF value - baseline value</description>
        <time_frame>baseline (week 0), week 6, week 12, week 18, week 24</time_frame>
        <population>The population analyzed for this outcome measure consisted of the subset of mITT patients who had at least one SMFPG value on treatment during the comparative period.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine</title>
            <description>Insulin glargine starting dose: 0.2 Unit per kilogram of body weight or 10 Units. Insulin titration (by 2 or 4 Units) every 3 days according to the median value of Fast Plasma Glucose of the last 3 days.</description>
          </group>
          <group group_id="O2">
            <title>Liraglutide</title>
            <description>Liraglutide dose: 0.6 mg/day during the first week, 1.2 mg/day during the second week and 1.8 mg/day until week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Self-Monitored Fasting Plasma Glucose (SMFPG) Measurements: Change From Baseline to the End of the Comparative Period</title>
          <description>SMFPG = mean value of Self-Monitored Fasting Plasma Glucose measurements over 3 consecutive days in the week before each visit
Value at the end of the comparative period defined as last available value during the comparative period (i.e. last-observation-carried-forward [LOCF] value)
Change = LOCF value - baseline value</description>
          <population>The population analyzed for this outcome measure consisted of the subset of mITT patients who had at least one SMFPG value on treatment during the comparative period.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="468"/>
                <count group_id="O2" value="452"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-65.25" spread="50.95"/>
                    <measurement group_id="O2" value="-37.23" spread="47.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Self-Monitored Fasting Plasma Glucose (SMFPG) Measurements: Change From Beginning to the End of the Extension Period</title>
        <description>SMFPG = mean value of Self-Monitored Fasting Plasma Glucose measurements over 3 consecutive days in the week before each visit
Value at the end of the extension period defined as last available value during the extension period (i.e. last-observation-carried-forward [LOCF] value)
Change = LOCF value - week 24 value</description>
        <time_frame>week 24, week 30, week 36, week 48</time_frame>
        <population>The population analyzed for this outcome measure consisted of the subset of mITT (extension) patients who had SMFPG value both at beginning of the extension and at least one value on treatment during the extension period.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine (Extension Period)</title>
            <description>Insulin glargine starting dose: 0.2 Unit per kilogram of body weight or 10 Units. Insulin titration (by 2 or 4 Units) every 3 days according to the median value of Fast Plasma Glucose of the last 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Self-Monitored Fasting Plasma Glucose (SMFPG) Measurements: Change From Beginning to the End of the Extension Period</title>
          <description>SMFPG = mean value of Self-Monitored Fasting Plasma Glucose measurements over 3 consecutive days in the week before each visit
Value at the end of the extension period defined as last available value during the extension period (i.e. last-observation-carried-forward [LOCF] value)
Change = LOCF value - week 24 value</description>
          <population>The population analyzed for this outcome measure consisted of the subset of mITT (extension) patients who had SMFPG value both at beginning of the extension and at least one value on treatment during the extension period.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-44.63" spread="45.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Self-Monitored 7-point Plasma Glucose (PG) Profile: Change From Baseline to the End of the Comparative Period</title>
        <description>Self-monitored 7-point plasma glucose profiles (before and 2 hours after the start of breakfast, lunch and dinner, and at bedtime) recorded on 3 consecutive days in the week before each visit
Value at the end of the comparative period defined as last available value during the comparative period (i.e. last-observation-carried-forward [LOCF] value)
Change = LOCF value - baseline value</description>
        <time_frame>baseline (week 0), week 12, week 24</time_frame>
        <population>The population considered was the mITT population but due to missing values, different subsets of this mITT population were analyzed for each time point of the profile.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine</title>
            <description>Insulin glargine starting dose: 0.2 Unit per kilogram of body weight or 10 Units. Insulin titration (by 2 or 4 Units) every 3 days according to the median value of Fast Plasma Glucose of the last 3 days.</description>
          </group>
          <group group_id="O2">
            <title>Liraglutide</title>
            <description>Liraglutide dose: 0.6 mg/day during the first week, 1.2 mg/day during the second week and 1.8 mg/day until week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Self-Monitored 7-point Plasma Glucose (PG) Profile: Change From Baseline to the End of the Comparative Period</title>
          <description>Self-monitored 7-point plasma glucose profiles (before and 2 hours after the start of breakfast, lunch and dinner, and at bedtime) recorded on 3 consecutive days in the week before each visit
Value at the end of the comparative period defined as last available value during the comparative period (i.e. last-observation-carried-forward [LOCF] value)
Change = LOCF value - baseline value</description>
          <population>The population considered was the mITT population but due to missing values, different subsets of this mITT population were analyzed for each time point of the profile.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="470"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before breakfast (N ig = 448 &amp; N l = 409)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-65.92" spread="50.29"/>
                    <measurement group_id="O2" value="-38.64" spread="46.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After breakfast (N ig = 440 &amp; N l = 397)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-66.70" spread="63.29"/>
                    <measurement group_id="O2" value="-55.35" spread="61.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before lunch (N ig = 438 &amp; N l = 404)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-50.16" spread="59.53"/>
                    <measurement group_id="O2" value="-39.13" spread="58.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After lunch (N ig = 433 &amp; N l = 406)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-43.00" spread="58.42"/>
                    <measurement group_id="O2" value="-41.82" spread="61.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before dinner (N ig = 434 &amp; N l = 400)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40.84" spread="58.88"/>
                    <measurement group_id="O2" value="-36.88" spread="58.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After dinner (N ig = 426 &amp; N l = 396)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.6" spread="61.74"/>
                    <measurement group_id="O2" value="-45.04" spread="60.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At bedtime (N ig = 380 &amp; N l = 351)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-43.11" spread="60.37"/>
                    <measurement group_id="O2" value="-44.06" spread="59.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Self-Monitored 7-point Plasma Glucose (PG) Profile: Change From Beginning to the End of the Extension Period</title>
        <description>Self-monitored 7-point plasma glucose profiles (before and 2 hours after the start of breakfast, lunch and dinner, and at bedtime) recorded on 3 consecutive days in the week before each visit
Value at the end of the extension period defined as last available value during the extension period (i.e. last-observation-carried-forward [LOCF] value)
Change = LOCF value - week 24 value</description>
        <time_frame>week 24, week 36, week 48</time_frame>
        <population>The population considered was the mITT population (extension) but due to missing values, different subsets of this population were analyzed for each time point of the profile.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine (Extension Period)</title>
            <description>Insulin glargine starting dose: 0.2 Unit per kilogram of body weight or 10 Units. Insulin titration (by 2 or 4 Units) every 3 days according to the median value of Fast Plasma Glucose of the last 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Self-Monitored 7-point Plasma Glucose (PG) Profile: Change From Beginning to the End of the Extension Period</title>
          <description>Self-monitored 7-point plasma glucose profiles (before and 2 hours after the start of breakfast, lunch and dinner, and at bedtime) recorded on 3 consecutive days in the week before each visit
Value at the end of the extension period defined as last available value during the extension period (i.e. last-observation-carried-forward [LOCF] value)
Change = LOCF value - week 24 value</description>
          <population>The population considered was the mITT population (extension) but due to missing values, different subsets of this population were analyzed for each time point of the profile.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before breakfast (N=143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-46.13" spread="44.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After breakfast (N=134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.67" spread="52.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before lunch (N=131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.32" spread="57.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After lunch (N=134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.50" spread="58.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before dinner (N=133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.56" spread="54.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After dinner (N=130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.28" spread="54.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At bedtime (N=127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.94" spread="52.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Weight: Change From Baseline to the End of the Comparative Period</title>
        <description>Change = Last weight value measured during the comparative period (LOCF value) - weight value at baseline</description>
        <time_frame>baseline (week 0), week 2, week 6, week 12, week 18, week 24</time_frame>
        <population>The population analyzed for this outcome measure consisted of the subset of mITT patients who had at least one weight value on treatment during the comparative period.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine</title>
            <description>Insulin glargine starting dose: 0.2 Unit per kilogram of body weight or 10 Units. Insulin titration (by 2 or 4 Units) every 3 days according to the median value of Fast Plasma Glucose of the last 3 days.</description>
          </group>
          <group group_id="O2">
            <title>Liraglutide</title>
            <description>Liraglutide dose: 0.6 mg/day during the first week, 1.2 mg/day during the second week and 1.8 mg/day until week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Body Weight: Change From Baseline to the End of the Comparative Period</title>
          <description>Change = Last weight value measured during the comparative period (LOCF value) - weight value at baseline</description>
          <population>The population analyzed for this outcome measure consisted of the subset of mITT patients who had at least one weight value on treatment during the comparative period.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.98" spread="3.95"/>
                    <measurement group_id="O2" value="-2.99" spread="3.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Weight: Change From Beginning to End of the Extension Period</title>
        <description>Change = Last weight value measured during the extension period (LOCF value) - weight value at beginning of the Extension Period (Week 24)</description>
        <time_frame>week 24, week 30, week 36, week 48</time_frame>
        <population>The population analyzed for this outcome measure consisted of the mITT population (extension).</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine (Extension Period)</title>
            <description>Insulin glargine starting dose: 0.2 Unit per kilogram of body weight or 10 Units. Insulin titration (by 2 or 4 Units) every 3 days according to the median value of Fast Plasma Glucose of the last 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Body Weight: Change From Beginning to End of the Extension Period</title>
          <description>Change = Last weight value measured during the extension period (LOCF value) - weight value at beginning of the Extension Period (Week 24)</description>
          <population>The population analyzed for this outcome measure consisted of the mITT population (extension).</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.35" spread="3.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Daily Dose of Insulin Glargine</title>
        <time_frame>week 1, week 2, week 6, week 12, week 24</time_frame>
        <population>The population considered was the mITT population but due to missing values, different subsets of this mITT population were analyzed at each week.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine</title>
            <description>Insulin glargine starting dose: 0.2 Unit per kilogram of body weight or 10 Units. Insulin titration (by 2 or 4 Units) every 3 days according to the median value of Fast Plasma Glucose of the last 3 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Daily Dose of Insulin Glargine</title>
          <population>The population considered was the mITT population but due to missing values, different subsets of this mITT population were analyzed at each week.</population>
          <units>Unit (U)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Start of treatment (N=472)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.39" spread="4.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 (N=470)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.74" spread="6.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (N=470)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.06" spread="8.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (N=470)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.67" spread="17.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (N=463)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.40" spread="26.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18 (N=454)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.65" spread="31.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (N=459)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.67" spread="34.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End comparative period (LOCF) (N=474)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.24" spread="33.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Daily Dose of Liraglutide</title>
        <time_frame>week 1, week 2, week 6, week 12, week 24</time_frame>
        <population>The population considered was the mITT population but due to missing values, different subsets of this mITT population were analyzed at each week.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide dose: 0.6 mg/day during the first week, 1.2 mg/day during the second week and 1.8 mg/day until week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Daily Dose of Liraglutide</title>
          <population>The population considered was the mITT population but due to missing values, different subsets of this mITT population were analyzed at each week.</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="470"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Start of treatment (N=470)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.60" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 (N=463)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.91" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (N=458)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.49" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (N=444)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.72" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (N=426)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.73" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18 (N=415)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.74" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (N=431)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.73" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End comparative period (LOCF) (N=470)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Daily Dose of Insulin Glargine Administered During the Extension Period</title>
        <time_frame>week 30, week 36, week 48</time_frame>
        <population>The population considered was the mITT population (extension) but due to missing values, different subsets of this mITT population were analyzed at each week.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine (Extension Period)</title>
            <description>Insulin glargine starting dose: 0.2 Unit per kilogram of body weight or 10 Units. Insulin titration (by 2 or 4 Units) every 3 days according to the median value of Fast Plasma Glucose of the last 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Daily Dose of Insulin Glargine Administered During the Extension Period</title>
          <population>The population considered was the mITT population (extension) but due to missing values, different subsets of this mITT population were analyzed at each week.</population>
          <units>Unit (U)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Start of treatment (N=154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.77" spread="4.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 30 (N=151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.49" spread="15.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 (N=150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.21" spread="23.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (N=151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.68" spread="27.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hypoglycemia Occurence: Number of Patients With at Least One Episode of Symptomatic / Severe Symptomatic Hypoglycemia During the Comparative Period</title>
        <description>Symptomatic hypoglycemia was defined as an event with clinical symptoms that were considered to result from hypoglycemia.
Severe symptomatic hypoglycemia was defined as an event with clinical symptoms that were considered to result from hypoglycemia, requiring the assistance of another person for active administration of carbohydrate, glucagon or other countermeasure because the patient could not treat him/herself due to acute neurological impairment directly resulting from the hypoglycemia (assistance by another person when the patient could have treated him/herself was not considered as requiring assistance)and one of the following criteria:
The event was associated with a measured PG level &lt; 36 mg/dL (2 mmol/L),
Or, in absence of PG value, the event was associated with neurological recovery attributable to the restoration of PG to normal, after oral carbohydrate, intravenous glucose or glucagon administration.</description>
        <time_frame>all across the comparative period (from week 0 to week 24)</time_frame>
        <population>The population analyzed was the safety population i.e. all randomized and treated patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine</title>
            <description>Insulin glargine starting dose: 0.2 Unit per kilogram of body weight or 10 Units. Insulin titration (by 2 or 4 Units) every 3 days according to the median value of Fast Plasma Glucose of the last 3 days.</description>
          </group>
          <group group_id="O2">
            <title>Liraglutide</title>
            <description>Liraglutide dose: 0.6 mg/day during the first week, 1.2 mg/day during the second week and 1.8 mg/day until week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Hypoglycemia Occurence: Number of Patients With at Least One Episode of Symptomatic / Severe Symptomatic Hypoglycemia During the Comparative Period</title>
          <description>Symptomatic hypoglycemia was defined as an event with clinical symptoms that were considered to result from hypoglycemia.
Severe symptomatic hypoglycemia was defined as an event with clinical symptoms that were considered to result from hypoglycemia, requiring the assistance of another person for active administration of carbohydrate, glucagon or other countermeasure because the patient could not treat him/herself due to acute neurological impairment directly resulting from the hypoglycemia (assistance by another person when the patient could have treated him/herself was not considered as requiring assistance)and one of the following criteria:
The event was associated with a measured PG level &lt; 36 mg/dL (2 mmol/L),
Or, in absence of PG value, the event was associated with neurological recovery attributable to the restoration of PG to normal, after oral carbohydrate, intravenous glucose or glucagon administration.</description>
          <population>The population analyzed was the safety population i.e. all randomized and treated patients.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="484"/>
                <count group_id="O2" value="481"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>symptomatic hypoglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>severe symptomatic hypoglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hypoglycemia Occurence: Number of Patients With at Least One Episode of Symptomatic / Severe Symptomatic Hypoglycemia During the Extension Period</title>
        <description>Symptomatic hypoglycemia was defined as an event with clinical symptoms that were considered to result from hypoglycemia.
Severe symptomatic hypoglycemia was defined as an event with clinical symptoms that were considered to result from hypoglycemia, requiring the assistance of another person for active administration of carbohydrate, glucagon or other countermeasure because the patient could not treat him/herself due to acute neurological impairment directly resulting from the hypoglycemia (assistance by another person when the patient could have treated him/herself was not considered as requiring assistance)and one of the following criteria:
The event was associated with a measured PG level &lt; 36 mg/dL (2 mmol/L),
Or, in absence of PG value, the event was associated with neurological recovery attributable to the restoration of PG to normal, after oral carbohydrate, intravenous glucose or glucagon administration.</description>
        <time_frame>all across the extension period (from week 24 to week 48)</time_frame>
        <population>The population analyzed was the safety population (extension) i.e. all treated patients during the extension period.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine (Extension Period)</title>
            <description>Insulin glargine starting dose: 0.2 Unit per kilogram of body weight or 10 Units. Insulin titration (by 2 or 4 Units) every 3 days according to the median value of Fast Plasma Glucose of the last 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Hypoglycemia Occurence: Number of Patients With at Least One Episode of Symptomatic / Severe Symptomatic Hypoglycemia During the Extension Period</title>
          <description>Symptomatic hypoglycemia was defined as an event with clinical symptoms that were considered to result from hypoglycemia.
Severe symptomatic hypoglycemia was defined as an event with clinical symptoms that were considered to result from hypoglycemia, requiring the assistance of another person for active administration of carbohydrate, glucagon or other countermeasure because the patient could not treat him/herself due to acute neurological impairment directly resulting from the hypoglycemia (assistance by another person when the patient could have treated him/herself was not considered as requiring assistance)and one of the following criteria:
The event was associated with a measured PG level &lt; 36 mg/dL (2 mmol/L),
Or, in absence of PG value, the event was associated with neurological recovery attributable to the restoration of PG to normal, after oral carbohydrate, intravenous glucose or glucagon administration.</description>
          <population>The population analyzed was the safety population (extension) i.e. all treated patients during the extension period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>symptomatic hypoglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>severe symptomatic hypoglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected throughout the study from the time the patient signed the informed consent until 7 days after the last dose of study treatment.</time_frame>
      <desc>The population analyzed was the safety population defined for each of the 2 periods (comparative and extension) as the patients treated with at least one dose of the study treatment during the considered period.</desc>
      <group_list>
        <group group_id="E1">
          <title>Comparative Period: Insulin Glargine</title>
          <description>Insulin glargine starting dose: 0.2 Unit per kilogram of body weight or 10 Units. Insulin titration (by 2 or 4 Units) every 3 days according to the median value of Fast Plasma Glucose of the last 3 days</description>
        </group>
        <group group_id="E2">
          <title>Comparative Period: Liraglutide</title>
          <description>Liraglutide dose: 0.6 mg/day during the first week, 1.2 mg/day during the second week and 1.8 mg/day until week 24 (comparative period)</description>
        </group>
        <group group_id="E3">
          <title>Extension Period: Insulin Glargine</title>
          <description>Following a treatment with liraglutide during the comparative period, those patients have received insulin glargine during the extension period.
Insulin glargine starting dose: 0.2 Unit per kilogram of body weight or 10 Units. Insulin titration (by 2 or 4 Units) every 3 days according to the median value of Fast Plasma Glucose of the last 3 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Diabetic gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Endocarditis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal behaviour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Oliguria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="239" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="146" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any abstract/manuscript for comment at least 20/45 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Trial Transparency Team</name_or_title>
      <organization>sanofi</organization>
      <email>Contact-us@sanofi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

